Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383999391> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4383999391 endingPage "1228" @default.
- W4383999391 startingPage "1219" @default.
- W4383999391 abstract "We evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of intravenous (IV) inclacumab, a fully human IgG4 anti-P-selectin monoclonal antibody in development for the treatment of sickle cell disease, at doses up to and exceeding those previously tested in healthy individuals.In this phase 1, open-label, single-ascending-dose study, 15 healthy participants were enrolled into cohorts receiving 20 mg/kg (n = 6) or 40 mg/kg (n = 9) IV inclacumab and observed for up to 29 weeks post-dose. Safety, PK parameters, thrombin receptor-activating peptide (TRAP)-activated platelet-leukocyte aggregate (PLA) formation, P-selectin inhibition, plasma soluble P-selectin, and anti-drug antibodies were characterized.Two inclacumab-related treatment-emergent adverse events were reported in 1 participant; no dose-limiting toxicities were observed. Plasma PK parameters were generally dose-proportional, with a terminal half-life of 13 to 17 days. Mean TRAP-activated PLA formation decreased within 3 h from the start of infusion, and inhibition was sustained for ~ 23 weeks. Mean P-selectin inhibition > 90% was observed up to 12 weeks post-dose. The mean ratio of free to total soluble P-selectin decreased rapidly from pre-dose to end of infusion, then increased gradually to 78% of the baseline ratio by week 29. Treatment-emergent anti-drug antibodies were observed in 2 of 15 participants (13%), without apparent impact on safety, PK, or PD.Inclacumab was well tolerated, with PK as expected for a monoclonal antibody against a membrane-bound target and a long duration of PD effects after both single IV doses, supporting a prolonged dosing interval.ACTRN12620001156976; registered November 4, 2020." @default.
- W4383999391 created "2023-07-13" @default.
- W4383999391 creator A5001812366 @default.
- W4383999391 creator A5004957581 @default.
- W4383999391 creator A5007299876 @default.
- W4383999391 creator A5025539602 @default.
- W4383999391 creator A5033210981 @default.
- W4383999391 creator A5033286474 @default.
- W4383999391 creator A5046643965 @default.
- W4383999391 creator A5070913409 @default.
- W4383999391 creator A5086044754 @default.
- W4383999391 date "2023-07-12" @default.
- W4383999391 modified "2023-09-25" @default.
- W4383999391 title "A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease" @default.
- W4383999391 cites W1512569924 @default.
- W4383999391 cites W1584253018 @default.
- W4383999391 cites W1588352485 @default.
- W4383999391 cites W1935749840 @default.
- W4383999391 cites W1966853009 @default.
- W4383999391 cites W203611039 @default.
- W4383999391 cites W2053495832 @default.
- W4383999391 cites W2055549139 @default.
- W4383999391 cites W2061367553 @default.
- W4383999391 cites W2075781353 @default.
- W4383999391 cites W2110641306 @default.
- W4383999391 cites W2161893570 @default.
- W4383999391 cites W2559643145 @default.
- W4383999391 cites W2592339311 @default.
- W4383999391 cites W2774644059 @default.
- W4383999391 cites W2902685885 @default.
- W4383999391 cites W3094818285 @default.
- W4383999391 cites W4211186710 @default.
- W4383999391 doi "https://doi.org/10.1007/s00228-023-03514-3" @default.
- W4383999391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37436495" @default.
- W4383999391 hasPublicationYear "2023" @default.
- W4383999391 type Work @default.
- W4383999391 citedByCount "0" @default.
- W4383999391 crossrefType "journal-article" @default.
- W4383999391 hasAuthorship W4383999391A5001812366 @default.
- W4383999391 hasAuthorship W4383999391A5004957581 @default.
- W4383999391 hasAuthorship W4383999391A5007299876 @default.
- W4383999391 hasAuthorship W4383999391A5025539602 @default.
- W4383999391 hasAuthorship W4383999391A5033210981 @default.
- W4383999391 hasAuthorship W4383999391A5033286474 @default.
- W4383999391 hasAuthorship W4383999391A5046643965 @default.
- W4383999391 hasAuthorship W4383999391A5070913409 @default.
- W4383999391 hasAuthorship W4383999391A5086044754 @default.
- W4383999391 hasBestOaLocation W43839993911 @default.
- W4383999391 hasConcept C111113717 @default.
- W4383999391 hasConcept C112705442 @default.
- W4383999391 hasConcept C126322002 @default.
- W4383999391 hasConcept C159654299 @default.
- W4383999391 hasConcept C197934379 @default.
- W4383999391 hasConcept C203014093 @default.
- W4383999391 hasConcept C2780868878 @default.
- W4383999391 hasConcept C542903549 @default.
- W4383999391 hasConcept C71924100 @default.
- W4383999391 hasConcept C98274493 @default.
- W4383999391 hasConceptScore W4383999391C111113717 @default.
- W4383999391 hasConceptScore W4383999391C112705442 @default.
- W4383999391 hasConceptScore W4383999391C126322002 @default.
- W4383999391 hasConceptScore W4383999391C159654299 @default.
- W4383999391 hasConceptScore W4383999391C197934379 @default.
- W4383999391 hasConceptScore W4383999391C203014093 @default.
- W4383999391 hasConceptScore W4383999391C2780868878 @default.
- W4383999391 hasConceptScore W4383999391C542903549 @default.
- W4383999391 hasConceptScore W4383999391C71924100 @default.
- W4383999391 hasConceptScore W4383999391C98274493 @default.
- W4383999391 hasFunder F4320307765 @default.
- W4383999391 hasIssue "9" @default.
- W4383999391 hasLocation W43839993911 @default.
- W4383999391 hasLocation W43839993912 @default.
- W4383999391 hasLocation W43839993913 @default.
- W4383999391 hasOpenAccess W4383999391 @default.
- W4383999391 hasPrimaryLocation W43839993911 @default.
- W4383999391 hasRelatedWork W1591820460 @default.
- W4383999391 hasRelatedWork W1899411185 @default.
- W4383999391 hasRelatedWork W1934038313 @default.
- W4383999391 hasRelatedWork W195682249 @default.
- W4383999391 hasRelatedWork W2227061539 @default.
- W4383999391 hasRelatedWork W2419379701 @default.
- W4383999391 hasRelatedWork W2594910449 @default.
- W4383999391 hasRelatedWork W2992709639 @default.
- W4383999391 hasRelatedWork W4298901412 @default.
- W4383999391 hasRelatedWork W4319655731 @default.
- W4383999391 hasVolume "79" @default.
- W4383999391 isParatext "false" @default.
- W4383999391 isRetracted "false" @default.
- W4383999391 workType "article" @default.